• Moleculin Biotech reported warrant exercises for 1,361,500 shares, generating approximately $2.7 million in gross proceeds, as of June 29, 2026.
  • The company also reported 7,065,000 common shares outstanding as of June 29, 2026, indicating the dilutive nature of the exercises.
  • The stock is trading at $2.88, down 19.4% today, reflecting investor sentiment following this dilutive capital raise.